Pearl

The Short Version

Pearl is an AI diagnostics platform for dentistry that has secured a first-mover advantage through regulatory clearance, a position it is now capitalizing on with a $58 million Series B round [TechCrunch, July 2024]. Founded in 2019 by Ophir Tanz, the company's core product, Second Opinion®, was the first AI software cleared by the FDA to read dental X-rays [TechCrunch, July 2024]. Tanz's background as the founder of GumGum, a computer vision company that scaled to over $100 million in revenue, provides a relevant operational track record for building and commercializing AI-powered visual analysis tools [Forbes, 2017]. The company operates a B2B software model, selling to dental practices and reporting aggressive top-line growth of 458% in 2023, though from a base of $11.1 million [TechCrunch, July 2024] [Latka]. The recent funding, led by Left Lane Capital at a $400 million post-money valuation, is the largest disclosed round in the dental AI category to date [Los Angeles Business Journal, July 2024].

Data Accuracy: YELLOW -- Key claims (FDA clearance, funding round, valuation) are confirmed by multiple outlets; revenue and growth metrics rely on single, unverified sources.

The Company in Brief

Pearl was founded in 2019 by Ophir Tanz, a solo founder who previously built and scaled GumGum, a computer vision company focused on advertising technology [Crunchbase]. The company operates from West Hollywood, California, targeting the dental diagnostics market with an AI-powered platform. Its primary milestone came in 2022 when it secured FDA clearance for its Second Opinion® software, a first for an AI dental diagnostic aid [TechCrunch, July 2024].

Key developments followed a clear funding cadence. Pearl raised an $11 million Series A in 2021, which supported the initial product development and regulatory efforts [Crunchbase]. The company then announced a $58 million Series B in July 2024, led by Left Lane Capital, which was reported as the largest single investment in the dental AI sector to date [Los Angeles Business Journal, July 2024]. This round valued the company at $400 million post-money [Los Angeles Business Journal, July 2024].

Operational milestones include building a team of 79 people by 2023 (estimated) and integrating its software with third-party platforms like Curve Dental's SuperHero™, which serves over 80,000 users [LinkedIn]. The company claims its technology is now used by dental practices across six continents [Dental Products Report].

Data Accuracy: YELLOW -- Key facts like founding date and funding rounds are confirmed by multiple sources. The 2023 team size and specific integration claims are based on single-source reports.

What They Have Built

Pearl's product strategy is built on a two-pillar platform, anchored by the first FDA-cleared AI diagnostic in its category. The company's primary offering, Second Opinion®, is a real-time radiologic aid that analyzes dental X-rays to detect pathologies like cavities and bone loss. According to the company, the software achieves a 94% diagnostic accuracy rate and is integrated directly into a practice's existing imaging workflow, providing visual overlays and annotations on radiographs [Pearl Website]. The core commercial claim is that this AI-assisted analysis drives a measurable business outcome: dentists using Second Opinion see, on average, a 30% increase in patient acceptance of recommended treatments [TechCrunch, July 2024].

The second pillar, Practice Intelligence®, is a suite of operational software tools designed to analyze practice data. The integration of both products into a single platform suggests a strategy to move beyond a point-solution diagnostic tool toward becoming a comprehensive practice management system. A significant deployment milestone is the integration of Pearl's software into the SuperHero™ platform by Curve Dental, which serves over 80,000 dental professionals [LinkedIn].

From a technology standpoint, the product is built on computer vision models trained to recognize dental pathologies. The company's first-mover regulatory status is a key differentiator; Second Opinion® holds FDA 510(k) clearance as a radiologic aid and is noted by the company as the only such software cleared for use in over 120 countries [Pearl Press Release].

Data Accuracy: YELLOW -- Product claims are sourced from the company website and press releases, with commercial outcomes (30% case acceptance boost) corroborated by a single third-party report. The integration with Curve Dental is noted on LinkedIn but lacks independent verification.

Market Size and Demand

The market for AI in dental diagnostics is defined less by its current size and more by the structural shift it represents, moving from a manual, subjective clinical process toward a quantified, software-augmented standard of care. Demand is driven by a confluence of clinical and economic factors. Dentists face persistent diagnostic variability and the challenge of patient case acceptance; Pearl's own claim that its software increases case acceptance by 30% speaks directly to a core revenue pain point for practices [Pearl Website]. The broader adoption of digital radiography over the past decade has created a standardized, digital asset base that is now amenable to computer vision analysis. Furthermore, an aging population and growing emphasis on preventative care are increasing the volume of diagnostic imaging, creating operational pressure that efficiency tools like Practice Intelligence® are designed to relieve [Perplexity Sonar Pro Brief].

Metric	Value
Global Dental Consumables Market (2023)	30 $B
AI in Medical Imaging Market (2030 est.)	4.5 $B

Data Accuracy: YELLOW -- Market sizing figures are from analogous, broader industry reports. Specific TAM/SAM for dental AI diagnostics is not confirmed by a dedicated third-party study.

Who Else Is Fighting for This

Pearl operates in a narrow but high-stakes segment where regulatory clearance is a primary moat, creating a near-term oligopoly of three venture-backed AI diagnostic providers.

Company	Positioning	Stage / Funding	Notable Differentiator
Pearl	AI-powered dental X-ray diagnostics platform	Series B / ~$69M total	First FDA-cleared AI dental diagnostic (Second Opinion®) in 2022
Overjet	AI analytics for dental insurers and providers	Series C / $53M raised March 2024	Focus on payer-side analytics and claims adjudication; valuation reported at $550M

Data Accuracy: YELLOW -- Competitor details are sourced from a single aggregated research brief; Pearl's own positioning and FDA status are publicly confirmed.

Opportunity

Pearl’s opportunity rests on transforming a fragmented, analog diagnostic process into a standardized, AI-driven workflow, creating a new category of clinical support software for a global dental industry that has been slow to adopt enterprise technology. The headline opportunity is for Pearl to become the de facto clinical operating system for dental practices worldwide. This outcome is plausible because the company has already secured the foundational regulatory and technical clearances that competitors lack. Its Second Opinion® platform is the first-and-only AI radiologic aid cleared for use in over 120 countries, a significant head start in a field where regulatory approval is a primary barrier to entry [Pearl Press Release].

Data Accuracy: YELLOW -- Key opportunity claims (regulatory clearance, integration) are from company sources; competitive benchmark and valuation are from single press reports.